<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01445691</url>
  </required_header>
  <id_info>
    <org_study_id>GCO 15-2034</org_study_id>
    <secondary_id>WCI1999-11</secondary_id>
    <secondary_id>R01CA176659</secondary_id>
    <secondary_id>R21CA186169</secondary_id>
    <secondary_id>IRB00051663</secondary_id>
    <nct_id>NCT01445691</nct_id>
  </id_info>
  <brief_title>More Complete Removal of Malignant Brain Tumors by Fluorescence-Guided Surgery</brief_title>
  <official_title>A Multicenter Phase II Study of 5-Aminolevulinic Acid (ALA) to Enhance Visualization and Resection of Newly Diagnosed or Recurrent Malignant Gliomas</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Constantinos Hadjipanayis</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>NX PharmaGen</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Icahn School of Medicine at Mount Sinai</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the safety and utility of 5-aminolevulinic acid&#xD;
      (ALA) for identifying your tumor during surgery. 5-ALA is not FDA approved at this time. When&#xD;
      the investigators remove the tumor from your brain, it is important that they remove all of&#xD;
      the tumor and not remove parts of normal brain. Sometimes this can be difficult because the&#xD;
      tumor can look like normal brain. In some brain tumors, 5-ALA can make the tumors glow red&#xD;
      under blue light. This may make it easier for your doctor to take out all of the tumor from&#xD;
      your brain. The purpose of this study is to:&#xD;
&#xD;
        -  Make sure that 5-ALA helps the doctor remove more of the tumor.&#xD;
&#xD;
        -  Make sure 5-ALA does not cause any side effects.&#xD;
&#xD;
      If you do not want to participate in this study, your doctor(s) will still do their best to&#xD;
      remove all of the tumor in your brain. Whether or not you join this study will not change&#xD;
      your treatment for your brain tumor.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <start_date>November 2015</start_date>
  <completion_date type="Anticipated">September 2016</completion_date>
  <primary_completion_date type="Anticipated">September 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Radicality of Brain Tumor Resection</measure>
    <time_frame>Within the first 48 hours after surgery</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival every 3 months after surgery</measure>
    <time_frame>Every 3 months until tumor progression on MRI</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Benign Neoplasms, Brain</condition>
  <condition>Brain Cancer</condition>
  <condition>Brain Neoplasms, Benign</condition>
  <condition>Brain Neoplasms, Malignant</condition>
  <condition>Brain Tumor, Primary</condition>
  <condition>Brain Tumor, Recurrent</condition>
  <condition>Brain Tumors</condition>
  <condition>Intracranial Neoplasms</condition>
  <condition>Neoplasms, Brain</condition>
  <condition>Neoplasms, Intracranial</condition>
  <condition>Primary Brain Neoplasms</condition>
  <condition>Primary Malignant Brain Neoplasms</condition>
  <condition>Primary Malignant Brain Tumors</condition>
  <condition>Gliomas</condition>
  <condition>Glioblastoma</condition>
  <arm_group>
    <arm_group_label>5-ALA (Gliolan)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Fluorescent substance to help visualize and remove as much tumor as possible without harming healthy tissue.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>5-ALA (Gliolan)</intervention_name>
    <description>20 mg/kg administered once 3-5 hours prior to surgery</description>
    <arm_group_label>5-ALA (Gliolan)</arm_group_label>
    <other_name>5-ALA</other_name>
    <other_name>Aminolevulinic acid</other_name>
    <other_name>Gliolan</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subjects must have a clinically documented primary brain tumor for which resection is&#xD;
             clinically indicated. Individuals with suspected newly diagnosed or recurrent&#xD;
             malignant gliomas will be considered eligible for the study. The anticipated histology&#xD;
             at resection should include: Anaplastic astrocytoma (10002224), Anaplastic ependymoma,&#xD;
             Anaplastic oligodendroglioma, Astrocytoma malignant NOS (10003572), Glioblastoma&#xD;
             (10018336), Glioblastoma multiforme (10018337), or Gliosarcoma (10018340).&#xD;
&#xD;
          -  Prior therapy is not a consideration in protocol entry.&#xD;
&#xD;
          -  Age 18-80.&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2 (Karnofsky ≥ 60%).&#xD;
&#xD;
          -  Life expectancy is not a consideration for protocol entry.&#xD;
&#xD;
          -  Subjects must have normal organ and marrow function as defined below:&#xD;
&#xD;
               -  Leukocytes ≥ 3,000/mL&#xD;
&#xD;
               -  Platelets ≥ 100,000/mL&#xD;
&#xD;
               -  Total bilirubin below upper limit of normal&#xD;
&#xD;
               -  Aspartate aminotransferase (AST) (SGOT)/alanine aminotransferase (ALT) (SGPT) ≤&#xD;
                  2.5 X institutional upper limit of normal&#xD;
&#xD;
               -  Creatinine below upper limit of normal OR&#xD;
&#xD;
               -  Creatinine clearance ≥ 60 mL/min/1.73 m² for patients with creatinine levels&#xD;
                  above institutional normal&#xD;
&#xD;
          -  The effects of aminolevulinic acid (ALA) on the developing human fetus are unknown.&#xD;
             For this reason, women of child-bearing potential and men must agree to use adequate&#xD;
             contraception (hormonal or barrier method of birth control; abstinence) prior to study&#xD;
             entry and for the duration of study participation. Should a woman become pregnant or&#xD;
             suspect she is pregnant while participating in this study, she should inform her&#xD;
             treating physician immediately. A pregnancy test will be performed for all women of&#xD;
             childbearing ability prior to surgery. Women who are pregnant will be excluded from&#xD;
             the trial.&#xD;
&#xD;
          -  Ability to understand and the willingness to sign a written informed consent document.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Tumors of or involving the midline, basal ganglia, or brain stem as assessed by MRI.&#xD;
&#xD;
          -  Subjects may not be receiving any experimental therapies.&#xD;
&#xD;
          -  History of allergic reactions attributed to compounds of similar chemical or biologic&#xD;
             composition to aminolevulinic acid (ALA). Patients should refrain from use of other&#xD;
             potential phototoxic substances (e.g. tetracyclines, sulfonamides,fluoroquinolones,&#xD;
             hypericin extracts) for 72 hours.&#xD;
&#xD;
          -  Personal or family history of porphyrias.&#xD;
&#xD;
          -  Uncontrolled intercurrent illness including, but not limited to ongoing or active&#xD;
             infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac&#xD;
             arrhythmia, or psychiatric illness/social situations that would limit compliance with&#xD;
             study requirements. Pregnant women are excluded from this study because aminolevulinic&#xD;
             acid (ALA) is of unknown teratogenic or abortifacient effects. Because there is an&#xD;
             unknown but potential risk for adverse events in nursing infants secondary to&#xD;
             treatment of the mother with aminolevulinic acid (ALA), breastfeeding should be&#xD;
             discontinued if the mother is treated with aminolevulinic acid (ALA).&#xD;
&#xD;
          -  Women who are pregnant will be excluded from the trial.&#xD;
&#xD;
          -  Prior history of GI perforation, diverticulitis, and/or peptic ulcer disease.&#xD;
&#xD;
          -  Inclusion of women and minorities: both men and women and members of all ethnic groups&#xD;
             are eligible for this trial.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Costas Hadjipanayis, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Icahn School of Medicine at Mount Sinai</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Emory University Hospital Midtown</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30308</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emory University Winship Cancer Institute</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emory Saint Joseph's Hospital</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30342</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Michigan</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Henry Ford Health System</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2016</verification_date>
  <study_first_submitted>September 30, 2011</study_first_submitted>
  <study_first_submitted_qc>September 30, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 4, 2011</study_first_posted>
  <last_update_submitted>May 13, 2016</last_update_submitted>
  <last_update_submitted_qc>May 13, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 17, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Icahn School of Medicine at Mount Sinai</investigator_affiliation>
    <investigator_full_name>Constantinos Hadjipanayis</investigator_full_name>
    <investigator_title>Professor and Chair, Neurosurgery</investigator_title>
  </responsible_party>
  <keyword>Benign Neoplasms, Brain</keyword>
  <keyword>Brain Cancer</keyword>
  <keyword>Brain Neoplasms, Benign</keyword>
  <keyword>Brain Neoplasms, Malignant</keyword>
  <keyword>Brain Tumor, Primary</keyword>
  <keyword>Brain Tumor, Recurrent</keyword>
  <keyword>Brain Tumors</keyword>
  <keyword>Intracranial Neoplasms</keyword>
  <keyword>Neoplasms, Brain</keyword>
  <keyword>Neoplasms, Intracranial</keyword>
  <keyword>Primary Brain Neoplasms</keyword>
  <keyword>Primary Malignant Brain Neoplasms</keyword>
  <keyword>Primary Malignant Brain Tumors</keyword>
  <keyword>Gliomas</keyword>
  <keyword>Glioblastoma</keyword>
  <keyword>Surgery</keyword>
  <keyword>5-ALA</keyword>
  <keyword>Aminolevulinic acid</keyword>
  <keyword>Fluorescence</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Glioblastoma</mesh_term>
    <mesh_term>Glioma</mesh_term>
    <mesh_term>Brain Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aminolevulinic Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

